Evidence map›Paper›PMID 25339764›Full record

ArticleJournal of virology2015

The sheep tetherin paralog oBST2B blocks envelope glycoprotein incorporation into nascent retroviral virions.

Lita Murphy, Mariana Varela, Sophie Desloire, Najate Ftaich, Claudio Murgia, Matthew Golder, Stuart Neil, Thomas E Spencer, Sarah K Wootton, Dimitri Lavillette and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Lita MurphyMedical Research Council, University of Glasgow, Centre for Virus Research, Glasgow, Scotland.
Mariana VarelaMedical Research Council, University of Glasgow, Centre for Virus Research, Glasgow, Scotland.
Sophie DesloireUMR754, Université Claude Bernard Lyon 1, Institut National de la Recherche Agronomique, Ecole Pratique des Hautes Etudes, SFR BioSciences Gerland, Lyon, France.
Najate FtaichUMR754, Université Claude Bernard Lyon 1, Institut National de la Recherche Agronomique, Ecole Pratique des Hautes Etudes, SFR BioSciences Gerland, Lyon, France.
Claudio MurgiaMedical Research Council, University of Glasgow, Centre for Virus Research, Glasgow, Scotland.
Matthew GolderMedical Research Council, University of Glasgow, Centre for Virus Research, Glasgow, Scotland.
Stuart NeilDepartment of Infectious Diseases, King's College London School of Medicine, London, England.
Thomas E SpencerDepartment of Animal Sciences and Center for Reproductive Biology, Washington State University, Pullman, Washington, USA.
Sarah K WoottonDepartment of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Dimitri LavilletteUMR5557 Microbial Ecology, Centre National de la Recherche Scientifique, Université Claude Bernard Lyon 1, Villeurbanne, France.
Christophe TerzianUMR754, Université Claude Bernard Lyon 1, Institut National de la Recherche Agronomique, Ecole Pratique des Hautes Etudes, SFR BioSciences Gerland, Lyon, France.
Massimo PalmariniMedical Research Council, University of Glasgow, Centre for Virus Research, Glasgow, Scotland.
Frédérick ArnaudUMR754, Université Claude Bernard Lyon 1, Institut National de la Recherche Agronomique, Ecole Pratique des Hautes Etudes, SFR BioSciences Gerland, Lyon, France frederick.arnaud@univ-lyon1.fr.
MRC University of Glasgow Centre for Virus Research · GBUniversité Claude Bernard Lyon 1 · FRKing's College London · GBUniversity of Guelph · CAWashington State University · US

Funding

Medical Research Council G0801822Wellcome Trust 098049
6 · The paper itself

Abstract

unlabelledBone marrow stromal cell antigen 2 (BST2) is a cellular restriction factor with a broad antiviral activity. In sheep, the BST2 gene is duplicated into two paralogs termed oBST2A and oBST2B. oBST2A impedes viral exit of the Jaagsiekte sheep retroviruses (JSRV), most probably by retaining virions at the cell membrane, similar to the "tethering" mechanism exerted by human BST2. In this study, we provide evidence that unlike oBST2A, oBST2B is limited to the Golgi apparatus and disrupts JSRV envelope (Env) trafficking by sequestering it. In turn, oBST2B leads to a reduction in Env incorporation into viral particles, which ultimately results in the release of virions that are less infectious. Furthermore, the activity of oBST2B does not seem to be restricted to retroviruses, as it also acts on vesicular stomatitis virus glycoproteins. Therefore, we suggest that oBST2B exerts antiviral activity using a mechanism distinct from the classical tethering restriction observed for oBST2A. IMPORTANCE: BST2 is a powerful cellular restriction factor against a wide range of enveloped viruses. Sheep possess two paralogs of the BST2 gene called oBST2A and oBST2B. JSRV, the causative agent of a transmissible lung cancer of sheep, is known to be restricted by oBST2A. In this study, we show that unlike oBST2A, oBST2B impairs the normal cellular trafficking of JSRV envelope glycoproteins by sequestering them within the Golgi apparatus. We also show that oBST2B decreases the incorporation of envelope glycoprotein into JSRV viral particles, which in turn reduces virion infectivity. In conclusion, oBST2B exerts a novel antiviral activity that is distinct from those of BST2 proteins of other species.

Indexed as

Virus AssemblyAnimalsGolgi ApparatusJaagsiekte sheep retrovirusMembrane GlycoproteinsProtein TransportSheepViral Envelope ProteinsVirionMembrane GlycoproteinsViral Envelope Proteins

Identifiers

PMID25339764
PMCPMC4301133
OpenAlexW2160630501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.